Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters








Year range
1.
Braz. j. infect. dis ; 13(5): 362-366, Oct. 2009. tab
Article in English | LILACS | ID: lil-544991

ABSTRACT

This study evaluated the effectiveness of two HAART regimens concomitant to rifampicin based tuberculosis (TB) treatment. Patients with TB/HIV diagnosis followed at the TB program between June 2000 and March 2005 were prospectively evaluated. The different HAART regimens in antiretrovirals (ARV) treatment naïve and ARV experienced patients were compared. The effectiveness of HAART was defined as a VL <80 copies/mL from month 4 to month 10 after TB treatment. One hundred and forty-two patients were included. Among these, 68 (47 percent) were treatment naïve and 76 (53 percent) previously exposed. Odds ratio (OR) in naïve patients treated with efavirenz (EFV) based regimen (n=42) compared to ritonavir/saquinavir (RTV/SQV) based regimen (n=26) was 8.0 (CI=1.67-38.35, p=0.008). OR from ARV experienced patients treated with RTV/SQV based regimen compared to EFV was 3.08 (CI=0.65-14.6, p=0.15), although with no statistical significance. Better effectiveness and tolerability were observed in antiretrovirals treatment naïve patients using EFV based regimens. Although not statistically significant, a favorable virologic response and a better tolerability were observed in the ARV experienced patients group who received a RTV/SQV based regimen.


Subject(s)
Adult , Female , Humans , Male , Middle Aged , Young Adult , Antiretroviral Therapy, Highly Active , Anti-HIV Agents/administration & dosage , Antitubercular Agents/administration & dosage , HIV Infections/drug therapy , Rifampin/administration & dosage , Tuberculosis/drug therapy , Follow-Up Studies , HIV Infections/complications , Treatment Outcome , Tuberculosis/complications , Viral Load , Young Adult
2.
J. pneumol ; 22(6): 295-8, nov.-dez. 1996. ilus, tab
Article in Portuguese | LILACS | ID: lil-199376

ABSTRACT

O desenvolvimento do câncer de pulmäo envolve múltiplas mudanças genéticas, incluindo ativaçäo de oncogenes e perda de atividade de gene supressor de tumor. Estudamos a expressäo do gene supressor de tumor p53 pela técnica de imuno-histoquímica (IH), em portadores de câncer de pulmäo de apresentaçäo central ou periférica. Realizou-se um estudo retrospectivo no Hospital Universitário Clementino Fraga Filho no Setor de Métodos Especiais (SME) do Serviço de Pneumologia de Clínica Médica da Faculdade de Medicina (FM) da Universidade Federal do Rio de Janeiro (UFRJ), com a colaboraçäo do Laboratório do Controle da Expressäao Gênica do Instituto de Biofísica da UFRJ e do Serviço de Anatomia Patológica do Departamento de Patologia...


Subject(s)
Lung Neoplasms/genetics
SELECTION OF CITATIONS
SEARCH DETAIL